Soraya Bekkali
SVP, EUCAN and International Business
About Delphine
Delphine brings extensive expertise in corporate affairs, policy engagement, patient advocacy, access strategy, strategic planning, and building high-performing teams. She joins from MSD, where she served as Associate Vice President, Sustainable Access Solutions within the Global Market Access organization.
Prior to MSD, Delphine held several senior leadership positions at Biogen and earlier in her career, she led European affairs and patient advocacy initiatives at LEEM, the French pharmaceutical industry association.
Throughout her career, Delphine has been driven by a commitment to improving outcomes for patients and helping healthcare systems sustainably adopt innovation. She has worked closely with patient communities across multiple therapeutic areas, including rare diseases, and understands the critical role that advocacy, policy and stakeholder partnerships play in accelerating diagnosis, access and support for patients and their families.
Related Content
Clinical Trials • October 15, 2026
Shaping the future of R&D with real world insights into rare disease
Studying a rare disease often involves working with fragmented information, much like piecing together scattered pages of different books, each offering part of the story but rarely forming a complete picture. Researchers face this challenge due to small, often underdiagnosed, patient populations and limited understanding of how these diseases progress over time.
Article • September 22, 2026
How can data, healthcare access and global collaboration advance health equity in rare diseases?
Living with a rare disease is inherently inequitable. More than 400 million people worldwide live with a rare disease, yet in many countries, it can take years to receive a diagnosis.1 Even once a diagnosis is confirmed, fewer than 10% of known rare diseases have an approved treatment.1 People living with rare diseases face inconsistent access to diagnostics, specialist care and treatments. These disparities are amplified in rural and lower-resource settings. The result is a persistent global gap between what is scientifically possible and what is practically accessible.
Thought Leadership • August 19, 2026
Advancing Rare Disease Research Through Patient-Centric Trial Design: Hear from Alexion R&D leader Gianluca Pirozzi
As Head of Development, Regulatory and Safety at Alexion, Gianluca Pirozzi channels his life’s experience with rare disease to inform his work at Alexion, ensuring clinical programmes are fueled by a patient-focused mindset.
Data Science and AI • August 13, 2026
AI to shorten the rare disease diagnosis
More than 10,000 rare diseases are known today, yet the path to diagnosis remains one of
medicine’s most complex challenges. Symptoms are often non-specific, allowing rare
conditions to hide in plain sight, especially when physicians may encounter them perhaps
once or twice in a career, if at all.
Thought Leadership • August 12, 2026
Keeping Patients at the Forefront of Rare Disease Innovation: Hear from Alexion R&D leader Seng H. Cheng
More than 10,000 rare diseases have been identified, yet fewer than 10% have an approved treatment available. For many patients and families, the urgency is compounded by rapidly progressive disease, long diagnostic journeys and limited therapeutic options.
Research and Development • August 12, 2026
Following the Science: The Evolution of Complement Inhibition in Rare Disease
Building on a legacy in complement science, we are advancing a new era of medicines focused on precision, specificity and improved outcomes for patients.
Health Equity • May 21, 2026
Understanding treatment impact and addressing disparities in rare disease care
Alexion’s leadership in rare disease is driven by the many individuals whose expertise, creativity and tenacity fuel our commitment to advancing innovative science.
Article • May 11, 2026
Tina’s Big Trip
Tina’s Big Trip is a heartfelt book that follow two sisters preparing for a journey to Italy as their family navigates the unseen complexities of rare disease.
Article • February 03, 2026
Pioneering new possibilities for the rare disease community
Rare Disease Day unites communities to drive strategies, funding, diagnosis and treatment, connecting local and global efforts for earlier, equitable care.
Diagnostics • September 17, 2025
Genomic Innovation to Support Newborn Screening of Rare Diseases
Today, while more than 10,000 rare diseases are known, recommended newborn screening panels cover only about 40 core conditions. This gap underscores the need for innovative approaches to expand the reach of newborn screening.
Veeva ID: GL/ALL/0121